Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

PAVLOVSKY, CAROLINA; VASCONCELOS CORDOBA, BIANCA; SANCHEZ, MARÍA BELÉN; MOIRAGHI, BEATRIZ; VARELA, ANA; CUSTIDIANO, ROSARIO; FERNANDEZ, ISOLDA; FREITAS, MARIA JOSEFINA; VENTRIGLIA, MARIA VERÓNICA; BENDEK, GEORGINA; MARIANO, ROMINA; MELA OSORIO, MARÍA JOSÉ; PAVLOVSKY, MIGUEL ANGEL; DE LABANCA, ANA GARCÍA; FONCUBERTA, CECILIA; GIERE, ISABEL; VERA, MASIEL; JUNI, MARIANA; MORDOH, JOSE; SANCHEZ AVALOS, JULIO CESAR; CUETO, GERARDO; MIRANDA, SILVIA; LEVY, ESTRELLA MARIEL; BIANCHINI, MICHELE

JOURNAL OF HEMATOLOGY AND ONCOLOGY

BIOMED CENTRAL LTD

Año: 2023 vol. 16

1756-8722

Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remission, and the prior time in deep molecular response (DMR) was associated with successful TFR. Luminex technology was used to characterize cytokines in plasma samples. Using machine learning algorithms, MCP-1 and IL-6 were identified as novel biomarkers and MCP-1low/IL-6low patients showed eightfold higher risk of relapse. These findings support the feasibility of TFR for patients in DMR and MCP-1/IL-6 plasma levels are strong predictive biomarkers.